CMS Expects to Launch CMS024 for the Treatment of Primary Liver Carcinoma Three Years Ahead of Plan in 2013

Hong Kong, Jan 28, 2011 - (ACN Newswire) - China Medical System Holdings Limited (SEHK:867), its subsidiary and Kangzhe Pharmaceutical Research and Development (Shenzhen) Limited (hereafter referred to as the "Applicant") held a successful roundtable meeting with the State Food and Drug Administration ("SFDA") of China. The meeting took place on 13th, October 2010, and the Applicant received a finalized minutes from the drug review centre of SFDA in late December 2010. The main purposes of the meeting were to review the historical data of Tyroserleutide and to explain and discuss the modification of clinical trial from the trial of Tyroserleutide intravenous drop to the trial of continuous intravenous injection with portable infusion pump as well as the phase III pump study design with the SFDA reviewers. The SFDA granted this meeting based on the initiative to expedite the development of National Class I New Drugs in China.